Organisation paid for research Program year 2024 Source: CMS Open Payments

WR Mount Vernon Clinical

Neither a doctor nor a teaching hospital

Research payments

$3,534,109

535 payments

Through program year 2024, WR Mount Vernon Clinical is reported as receiving $3,534,109 in research payments, across 535 payments.

By program year

3 rows

Year	Kind	Amount	Payments
2024	Research	$45,258	3
2023	Research	$1,475,192	308
2022	Research	$2,013,659	224

Breakdown

Who paid Research payments · program years 2022–2024

Moderna TX, Inc. $2,945,356 524 payments
Bavarian Nordic A/S $588,753 11 payments

Studies the money was for Research payments · program years 2022–2024

A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age $2,564,644 34 payments
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 $576,753 9 payments
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older $159,918 271 payments
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older $121,340 193 payments
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age $76,975 17 payments
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months $16,479 8 payments
Nct05329220 $12,000 2 payments
Moderna Vaccine mRNA-1345 Observational Respiratory Syncytial Virus (RSV) Study $6,000 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.